UMIN-CTR Clinical Trial

Recruitment status Terminated
Unique ID issued by UMIN UMIN000018846
Receipt No. R000021712
Official scientific title of the study IOP-lowering effect lasting for 24 hours of Tapcom combination ophthalmic solution switched from Tapros ophthalmic solution 0.0015% and Timoptol XE Ophthalmic Solution 0.5%.
Date of disclosure of the study information 2015/08/29
Last modified on 2017/02/16 (Ver. 3)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study IOP-lowering effect lasting for 24 hours of Tapcom combination ophthalmic solution switched from Tapros ophthalmic solution 0.0015% and Timoptol XE Ophthalmic Solution 0.5%.
Title of the study (Brief title) IOP-lowering effect lasting for 24 hours of Tapcom combination ophthalmic solution switched from Tapros ophthalmic solution 0.0015% and Timoptol XE Ophthalmic Solution 0.5%.
Region
Japan

Condition
Condition primary open angle glaucoma
Classification by specialty
Ophthalmology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate IOP-lowering effect lasting for 24 hours of Tapcom combination ophthalmic solution in primary open angle glaucoma patients who switch treatment from Tapros ophthalmic solution 0.015% and Timoptol XE Ophthalmic Solution 0.5%.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Mean 24-hour IOP after the drug was administered for 8 weeks
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Switching from Tapros ophthalmic solution 0.0015% and Timoptol XE Ophthalmic Solution 0.5% to Tapcom combination ophthalmic solution.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients with unilateral or bilateral primary open angle glaucoma
Patients who can visit the hospital according to the observation/test schedule determined in the study protocol
Key exclusion criteria Patients with some corneal abnormality or other diseases which may interfere with accurate IOP measurement using Goldmann applanation tonometer
Patients with a history of corneal refractive surgery
Patients with active extraocular disease, inflammation or infection in the eye(s) or eyelid(s)
Patients with allergy to the ingredients used in the present study
Pregnant, lactating women or women who may be pregnant, and women who wish to be pregnant or can not conduct appropriate contraception during the study period
Patients who are contraindicated to beta blockers (those who with bronchial asthma or insufficiently controlled heart failure)
Target sample size 20

Research contact person
Name of lead principal investigator Kenji Nakamoto
Organization Nippon Medical School Hospital
Division name Ophthalmology
Address 1-1-5 Sendagi, Bunkyo, Tokyo, Japan
TEL 03-3822-2131
Email makken45@nms.ac.jp

Public contact
Name of contact person Kenji Nakamoto
Organization Nippon Medical School Hospital
Division name Ophthalmology
Address 1-1-5 Sendagi, Bunkyo, Tokyo, Japan
TEL 03-3822-2131
Homepage URL
Email makken45@nms.ac.jp

Sponsor
Institute Nippon Medical School Hospital
Institute
Department

Funding Source
Organization Santen Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 08 Month 29 Day

Progress
Recruitment status Terminated
Date of protocol fixation
2015 Year 06 Month 19 Day
Anticipated trial start date
2015 Year 06 Month 19 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2015 Year 08 Month 29 Day
Last modified on
2017 Year 02 Month 16 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021712